and motivates future structural studies to understand the structural basis for EGFR kinase specificity. Results from these studies define the binding mode of a novel third-generation mutant-selective EGFR TKI lazertinib with improved dose-limiting toxicity as well as ontarget potency and selectivity and serves as a noteworthy example for developing nextgeneration kinase inhibitors.